Nanosphere, Inc. Announces FDA Submission of 510(k) Documentation for Its Verigene Cardiac Troponin I Assay

Published: Nov 18, 2009

NORTHBROOK, Ill., Nov. 18, 2009 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today it submitted a 510(k) application to the FDA for its cardiac troponin I test that the company believes will provide early and sensitive diagnosis of myocardial infarction and risk stratification for acute coronary syndromes.

Back to news